Dupont Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Dupont Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-497	Closed	-$178K	–	1727
2021 Q1	$178K	Buy	+497	New	+$220K	﹤0.01%	1289
2019 Q1	–	Sell	-413	Closed	-$358K	–	1177
2018 Q4	$358K	Hold	413	–	–	0.01%	844
2018 Q3	$427K	Hold	413	–	–	0.01%	744
2018 Q2	$379K	Hold	413	–	–	0.01%	769
2018 Q1	$402K	Buy	+413	New	+$376K	0.01%	712

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Dupont Capital Management's ATRA Position: Q2 2021 in Review

Dupont Capital Management sold out of Atara Biotherapeutics (ATRA) in Q2 2021, closing a stake of 497 shares — an estimated $178K sold.

Dupont Capital Management first reported a position in ATRA in Q1 2018 and held it in 5 quarters. The position peaked at $427K in Q3 2018. 145 funds tracked by Wall St. Rank hold ATRA as of Q2 2021.

Dupont Capital Management reported no remaining Atara Biotherapeutics position as of Q2 2021 after selling out during the quarter.
Dupont Capital Management sold 497 Atara Biotherapeutics shares in Q2 2021, an estimated $178K.
Dupont Capital Management first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 5 quarters.
Dupont Capital Management's Atara Biotherapeutics position peaked at $427K in Q3 2018.
145 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2021.

Based on Dupont Capital Management's 13F filing for Q2 2021, filed 30 Jul 2021.